New Delhi: The initial public offering (IPO) of Anthem Biosciences Ltd got fully subscribed on the day two of bidding on Tuesday.
The initial share sale received bids for 5,24,97,042 shares against 4,40,70,682 shares on offer, according to NSE data till 10:54 am, translating into 1.19 times subscription.
The category for non-institutional investors fetched 2.94 times subscription while the quota for retail individual investors (RIIs) got subscribed 91 per cent. Qualified institutional buyers (QIBs) part received 38 per cent subscription.
Anthem Biosciences has raised Rs 1,016 crore from anchor investors.
The Rs 3,395-crore IPO of the Bengaluru-based firm will close on Wednesday. The price band has been fixed at Rs 540-570 per share.
Since the IPO is entirely an offer for sale (OFS), the company will not receive any funds from the issue, and the proceeds will go to the selling shareholders.
Anthem is into innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing.
It also manufactures and sells complex, specialised fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars.
JM Financial, Citigroup Global Markets India, J P Morgan India, and Nomura Financial Advisory and Securities (India) are the book running lead managers for the issue.
(Disclaimer: This story is from the syndicated feed. Nothing has been changed except the headline.)
